Fig. 3From: Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancerShown are serial MRI and PET data for example patients: A a stage IIIC triple-negative (ER−, PR−, HER2−, Ki67 83%) intraductal carcinoma who achieved RCB 0 after neoadjuvant treatment; B a stage IIIA luminal B (ER+, PR− HER2−, Ki67 30%) intraductal carcinoma who had residual disease (RCB II) after neoadjuvant treatmentBack to article page